|
tbar.gif
Click
here to
submit entries
|
|
-
Strategic Briefing
- Pressure
BioSciences
CEO
and Founder Richard T. Schumacher CHI PharmaWeek e-NewsDescribes Pressure Cycling Technology and its Many Applications, by Laurie Sullivan, Senior Editor, PharmaWeek
-
Strategic Briefing
- Finding the Magic in Fixed
Combinations
by John Ansell, Director, John Ansell Consultancy
-
Novartis Plunges into Hepatitis C
Market, by Lucy Sannes, Ph.D., President, Sannes and Associates
-
Real-Time
Trials, by Mark D. Uehling, Bio-IT World
- Apoptosis Field Springs to
Life
by Malorye Branca and Lucy Sannes, PhD,--
May 25, 2006
-
Pharma Weighs Its Options in
Asia,--
May 19, 2006
by Laurie Sullivan, Senior Editor, PharmaWeek
- J&J's Peter Juhn on The Value
Proposition --
May 11, 2006
by Malorye A. Branca, Editor-in-Chief, PharmaWeek
-
Integrity
of Clinical Samples Crucial to Quest for New Biomarkers
Laurie Sullivan, Senior Editor, PharmaWeek
-- May 5, 2006
- Enhanced Pharmaceutical Productivity Calls for Increased
Collaboration, by Laurie Sullivan, Senior Editor, PharmaWeek
-- April 28, 2006
-
Wyeth's
Orest Hurko on How Biomarkers Will Help
by Malorye A. Branca, Editor-in-Chief, PharmaWeek
-- April 20, 2006
-
GSK's Allen Roses: Personal Medicine's Rosy Picture, by Kevin
Davies, Editor-in-Chief, Bio-IT World
-- April 13, 2006
- Flash Report
Decoding the Genetics of Common
Disease, by Kevin Davies, Editor-in-Chief, Bio-IT World
- How
Pfizer Defines Biomarkers: Three Oncology Case Studies,
by Malorye A. Branca, Editor-in-Chief, PharmaWeek -- March
29, 2006
PerkinElmer
CSO Neil Cook on Agilix Acquisition
By Malorye A. Branca, Editor-in-Chief, PharmaWeek
-- March 23, 2006
- Bringing
Lentiviral Vectors to Market as Research Products and Therapies: Boro
Dropulic, Founder and CEO, Lentigen
-- March 15, 2006
-
Wyeth's Mahdi Fawzi on Embracing Attrition to Improve
Productivity,
by Malorye A. Branca, Editor-in-Chief, PharmaWeek
-- March 3, 2006
- Flash Report
Start-Ups Strut Stuff at CHI Partnering
Meeting
by By Malorye A. Branca, Editor-in-Chief, PharmaWeek
-- March 3, 2006
- Merck's
Peter S. Kim Shares New Game Plan at BIO CEO Meeting
By Malorye A. Branca, Editor-in-Chief, PharmaWeek
-- March 24, 2006
- Multi-Target Kinase Inhibitors Hitting the Market,
by Malorye A. Branca, editor-in-chief, PharmaWeek, and Lucy Sannes, Ph.D., President, Sannes and Associates
-- Feb. 9, 2006
- Biogenerics Part II: Momenta's Big
Move, by Phillips Kuhl, President of Cambridge Healthtech Institute, and Malorye A. Branca, Editor-in-Chief,
PharmaWeek
-- Feb. 2, 2006
- Biogenerics
Part I: Set to Make Real Inroads or Not?
By John Ansell, Director, John Ansell Consultancy
-- Jan. 26, 2006
- Hot
Targets: CCR2 in Inflammatory Disease
By Lucy Sannes, Ph.D., President, Sannes and Associates
-- Jan. 19, 2006
- Outlook
2006: Top Developments to Watch
By Malorye A. Branca, editor-in-chief, PharmaWeek
-- Jan. 12, 2006
- Breaking the Obesity Barrier: Near-Term Prospects for
Breakthrough
Treatments, by Allan B. Haberman, Ph.D., Haberman Associates, The Biopharmaceutical Consortium
-- Dec. 22, 2005
- Flash Report
Cancer
Therapeutic Update from AACR: New Combinations, Targets, and Types
of Markers
-- Dec. 15, 2005
Executive Angle
-- Dec. 8, 2005
- Flash Report Dozens
of Companies Vying for Bits of Bird Flu Market
-- Dec. 8, 2005
- Flash Report ,
-- Dec. 1, 2005
- Flash Report Biotechs
Bask in Better Financial Climate
-- Dec. 1, 2005
- Making the Most of
Statins: Risks and Benefits of Bringing Blockbusters into New Arenas, by John
Ansell, Director, John Ansell Consultancy -- Nov. 14, 2005
- Public
Perception of Genomics/Genetic Testing: CGAT Survey Results
-- Nov.
4, 2005
|
|
|
|
DrugBank
Database in Commercial Partnership |
|
Deal with GenomeQuest
exchanges access privileges, clinical data for
funding.
By Kevin Davies
Bio-IT World
Feb. 1, 2008
| The Canadian developers of a popular drug database
have partnered with a software company in an unusual
win-win relationship. The deal exchanges short-term
funding that might ensure the long-term survival of
the database in return for exclusive data access to
the commercial partner, GenomeQuest.
Read
More
|
|
|
